



ONCO-INNOVATIONS

# Transforming Oncology Through Science and AI Technology

CSE: ONCO | FSE: W1H

FEBRUARY 2025





# Forward Looking Statements and Disclaimer



## FORWARD LOOKING STATEMENTS

This presentation contains “forward looking information” within the meaning of applicable Canadian securities legislation. Wherever possible, words such as “plans”, “expects”, or “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, have been used to identify forward looking information. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Onco-Innovations Inc. (the “Company”) to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward looking statements are based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. Management believes that the assumptions and expectations reflected in such forward looking statements are reasonable.

## MARKET DATA DISCLAIMER

This presentation includes market and industry data that has been obtained from third party sources including publications from various industries, and where appropriate, certain numbers, including dollar amounts, have been rounded out by us to avoid lengthy numbers. We believe that this industry data is accurate and that its estimates and assumptions are reasonable; however, there are no assurances as to the accuracy or completeness of this data. Third party sources generally state that the information contained therein has been obtained from sources believed to be reliable; however there are no assurances as to the accuracy or completeness of included information. Although the data is believed to be reliable, we have not independently verified any of the data from third party sources referred to in this presentation or ascertained the underlying economic assumptions relied upon by such sources. nager of a syndicate. If a firm is less established, the firm, and not the investment bank, tends to make the pitch to secure the relationship.





# Executive Summary



Onco-Innovations is Transforming Oncology  
Through Science, AI, and Strategic Acquisitions



## Leveraging AI, Revolutionizing Oncology

Committed to revolutionizing oncology care by delivering life-saving treatments through precision medicine and cutting-edge AI technologies.



## Drug Discovery Pipeline

Proprietary colorectal cancer therapies addressing a \$15 billion market opportunity with preclinical validation and human trials on the horizon.



## Strategic Acquisition of Inka Health

Integration of Inka's AI-driven Synograph™ platform enhances diagnostics, accelerates treatment timelines, and strengthens Onco's competitive edge plus big pharma partners and more.



## \$200B Global Oncology Market

Positioned in a \$200 billion global oncology market, with the precision medicine market projected to grow from \$87.5 billion in 2023 to \$249.24 billion by 2030, achieving a total growth of 184.8%.





# Global Cancer Market Size

An Immense Investment Opportunity in Oncology




135%

Aggregate Growth Expected by 2032

- ✓ Global cancer cases are projected to rise by **47% by 2040**
- ✓ CAGR of **8.9%**
- ✓ Existing treatment gaps in precision medicine and early diagnostics
- ✓ **Addressable market:** Colorectal cancer alone represents a \$18 billion market
- ✓ Unmet needs include faster diagnostics and cost-effective therapies

## 10 Year Growth Projection





# Colorectal Cancer: A Critical Focus

## Addressing the Second Leading Cause of Cancer Deaths

### Global Impact

- **Affects 1.9M people annually**; causes 700,000 deaths worldwide
- **4th most common cancer**; sporadic cases (no family history) account for 70%

### Early Detection Matters

- **90% survival** rate for early-stage diagnosis vs. **14%** for late-stage
- 40% of sporadic CRC patients die due to distant metastases

### Challenges


- Limited access to precision medicine
- Ineffective treatments for advanced cases
- Diagnostic delays worsen outcomes

### Onco's Solutions

- ✓ **Innovative Therapies**: Advanced drug treatments for aggressive CRC
- ✓ **AI Detection**: Tools to identify cancer earlier and improve survival rates
- ✓ **Patient-Centered Care**: Bridging treatment gaps for better outcomes



## What is Colorectal Cancer?



### CRC Incidence Rate is:



- **35%-40%** more common in men than women<sup>2</sup>








Our 100% Owned Proprietary Lead Drug Candidate, Utilizing Polynucleotide Kinase 3'-Phosphatase (PNKP) inhibitors Platform Technology



## Cancer-Targeted Approach

- ✓ **Proprietary Formula:** Prevents DNA repair to eliminate cancer cells
- ✓ **Enhanced Delivery:** Nanoparticles ensure precision targeting
- ✓ **Optimized Results:** Works with chemo/radiation to improve outcomes and **reduce side effects.**



## Key Advantages

- ✓ **Scalable across multiple cancer types**
- ✓ Supported by **5 patents** safeguarding innovation and market leadership
- ✓ Proprietary Precision Kinase Network Profiling (PKNP) powers **Onco10™**, our revolutionary drug candidate

Effective against **multiple cancers** & Synergizes with **tumor-suppressing genes (SHP-11, PTEN2).**

Onco10™ is a proprietary term of Onco Innovations. Trademark registration is pending.






# Drug Discovery Pipeline - Colorectal Drug Success



## Preclinical Validation: Tumor Reduction and Survival Impact Groundbreaking Results in Animal Models



- The figure above clearly demonstrates that the patented drug formulation effectively reduced tumor size in mice.

- ✓ Recent studies reveal a significant breakthrough with **NP/A83B4C63**, a novel nanoparticle formulation demonstrating efficacy in slowing down the growth of PTEN-/- tumors.
- ✓ Compared to placebo, NP/A83B4C63 showcased remarkable performance, significantly reducing tumor growth.
- ✓ High specificity and low toxicity profiles further validate its potential for safe and effective human application.






# Path to Regulatory Approval



## A Clear Regulatory Roadmap for PKNP Drug Candidates





# World-Class Leadership Team



Diverse experts with decades of combined experience in oncology, AI, pharmaceuticals, and clinical research.

Notable achievements include leading global trials, advancing precision oncology technologies, and contributions to groundbreaking therapies.



**Thomas O'Shaughnessy**

▪ CEO

Mr. O'Shaughnessy, MSc (Oxford), brings 23+ years of expertise in healthcare strategy, policy, and operations. As a former Partner at Deloitte Canada, he led health industry growth nationally and spearheaded digital health initiatives. Currently, as Managing Principal at Carnarvon Strategies, he focuses on driving value creation and strategy execution in healthcare and life sciences.



**Richard Heinzl**

▪ Director

Founder of Doctors Without Borders Canada, recipient of the Nobel Peace Prize (1999). Current CEO of My Next Health Inc., pioneering functional genomics. Former Global Medical Director at WorldCare, a Harvard-associated virtual medicine company. Holder of degrees from McMaster, Harvard, and Oxford, with global expertise in genomics and healthcare innovation.



**Nico Mah**

▪ CFO and Corp Secretary

Mr. Mah is a Chartered Professional Accountant and has nearly eight years' of experience in auditing and public accountancy, having been an associate and subsequently a manager at PricewaterhouseCoopers LLP, the global audit and assurance, tax, deals and consulting firm from September 2015 to January 2023.





# Leadership Cont'd



**Zachary Stadnyk**

▪ Director

Mr. Stadnyk is a distinguished public company executive with over fifteen years of experience leading multi-million-dollar initiatives across Healthcare, Wellness, Technology, Cannabis, and Private Equity sectors. Mr. Stadnyk is the chairman and a director of Right Season Investments Corp., a venture capital, investment and advisory firm listed on the TSXV, since June 2024. Mr. Stadnyk recently led the Life Sciences and Innovation sectors at the TMX Group. Mr. Stadnyk is also the CFO of Redwood AI Inc.



**Graydon Bensler**

▪ Director

Mr. Bensler is a financial professional and analyst with over seven years of experience in financial consulting and management for both private businesses and US/Canadian publicly traded companies and is a Chartered Financial Analyst (CFA). He currently serves as the CEO of Elevai Labs, a publicly listed company on the NASDAQ Exchange.



**Maximilian Justus**

▪ Director

Mr. Justus is a public company executive with experience in the fashion and apparel industry. Mr. Justus has served as the Chief Executive Officer and Director of Grounded People Apparel since 2020, where he has been focused on driving strategic initiatives, overseeing operations, and expanding market share.





# Scientific Advisory Board

Our Scientific Advisory Board provides unparalleled expertise in oncology, drug development, and AI applications



## Dr. Michael Weinfeld

Dr. Weinfeld, Professor of Oncology at the University of Alberta and Senior Scientist at Alberta Health Services, brings over 40 years of expertise in cancer research. Based at the Cross Cancer Institute, his groundbreaking work focuses on DNA damage and repair, advancing therapies to make cancer cells more vulnerable to radiotherapy and chemotherapy.



## Dr. Fadia Saad

Dr. Saad, PhD, MBA, is the Chief Business Development Officer at ASEP Medical Holdings Inc., bringing 25+ years of experience in biotechnology. With expertise spanning autoimmune diseases, oncology, and infectious diseases, she combines scientific and financial acumen to drive product and business development in cutting-edge biotech companies.



## Dr. Frederick West

Dr. West, Allard Research Chair in Oncology at the University of Alberta, specializes in chemical synthesis and structural modification of organic molecules. A key contributor to developing DNA repair inhibitors, his innovative work enhances the efficacy of chemotherapy and radiotherapy in cancer treatment.



## Dr. Afsaneh Lavasanifar

Dr. Lavasanifar, Professor in Pharmaceuticals at the University of Alberta, is a global leader in polymerbased drug delivery systems, focusing on nano-carriers for cancer immunotherapy and anti-inflammatory treatments. With over 170 publications, 10 patents, and prestigious awards, she also serves as Scientific Chief Officer at Meros Polymers Inc., advancing innovative therapeutics from her lab's technology.












# Big Pharma Industry Comparables



## Scaling Innovation: Benchmarking Onco-Innovations Against Industry Leaders with Clinical Oncology Assets

Data as of **January 21st, 2025**

	Company	Clinical Trial	Phase	Market Cap	Share Price
	AstraZeneca (Nasdaq: AZN)	Ovarian Carinoma	2	USD \$109.BB	\$68.00
	Abbott (NYSE: ABT)	BCRA-mutated Ovarian Cancer	1	USD \$218B	\$116.79
	Pfizer (NYSE: PFE)	Advanced Solid Tumours	1	USD \$147.4B	\$26.64
	Eli Lilly (NYSE: LLY)	Non-small Cell Lung Cancer	1	USD \$745.9B	\$742.350
	Bristol Myers Squibb (NYSE: BMJ)	Advanced Solid Tumours, Lymphomas	1	USD \$121B	\$57.04
	Merck & Co (NYSE: MRK)	Advance Non-small Cell Lung Cancer	2	USD \$242B	\$96.24
	<b>Onco-Innovations (CSE: ONCO)</b>	<b>Advanced Solid Tumours</b>	<b>1</b>	<b>CAD \$67.3M</b>	<b>\$1.69</b>





# Acquisition Target: INKA Health AI

Strategic Oncology Focused Growth Ahead  
LOI Announced January 21, 2025

[www.inkahealth.ai](http://www.inkahealth.ai)



Trusted By:




**REGENERON**



# Inka Scientific Leadership Team

World-Class Oncology-AI Focused Team




**Paul Arora, CEO, PhD**

- Epidemiologist
- Successfully exited founder of Lighthouse Outcomes
- 50+ scientific publications  
A decade of senior leadership
- Positions in global consulting



**Stephen Jones, PhD**

- Molecular Geneticist
- Director Bioinformatics, Genome BC
- Bioinformatics Platform, Genome BC
- Founder of Ifowonco Bioinformatics Inc. and Alamyra Health
- PBCCanada Research Chair in Computational Genomics



**Winson Cheung, MD**

- Medical Oncologist (GI)
- Head of Oncology Outcomes Research Group 300+ scientific publications
- Former CDA Expert Review Committee member & Flatiron Health Advisor
- 20MM+ in scientific funding



**James Obinski, PhD**

- Scientific Advisor
- **Nobel Peace Prize Recipient**
- Globally renowned humanitarian, scholar, and Officer of the Order of Canada.
- Founding Director of York University's Dahdaleh Institute for Global Health Research
- Former International Council President (Doctors Without Borders)







# Synograph™ is Personalized, Tailored, Precision Medicine Cancer Therapy.

Our platform empowers drug developers with insights and advanced AI tools to boost early clinical success and optimize decision making for precision medicine oncology treatment and therapies.





# Transforming Oncology Through SynoGraph™ AI



**Inka** Health



**ONCO-INNOVATIONS**

## Transformative Target Acquisition to Lead the Future of Oncology

### Acquisition Details

- **100% Acquisition of INKA Health AI** for \$3M in Onco common shares
- Closing: **February 14, 2025**, subject to due diligence and approvals

### SynoGraph™ AI Integration

- **Breakthrough AI:** Accelerates diagnosis and delivers personalized treatments, cutting diagnostic delays by up to **50%**
- Enhances drug development timelines and boosts pipeline efficiency. Complimenting Onco's technology and pipeline

### Strategic Big Pharma Partnerships

- Trusted by **top pharmaceutical leaders**
- Scaling global impact through established collaborations

### A World-Class Nobel Prize Winning Oncology Team

- **Global Experts** in AI, oncology, and precision medicine
- Proven success in partnerships **with leading pharma companies**






# Inka's Proprietary and Patented AI SynoGraph™



Synograph™ is Inka's flagship asset, a revolutionary AI-enabled platform that enhances the precision and efficiency of oncology diagnostics and treatment planning.



## Prevention

Analyzes risk factors to help patients reduce their disease risks

## Diagnosis

Identifies root molecular causes of cancer. Uncovers targeted treatment options that may be overlooked

## Treatment

Recommends targeted therapies that are safer and potentially more effective

## Personalized Approach

Tailors therapies to each patient's unique molecular profile





# Precision Medicine Market Growth



## 185%

growth expected in 7 years


**Precision medicine**, powered by Inka's **Synograph™ AI**, utilizes patient-specific data—such as genetic and molecular profiles—to deliver highly targeted and effective oncology diagnostics and treatment plans, drastically improving outcomes and reducing time- to-treatment.



### Current Market Size

The global precision medicine market was valued at approximately **\$87.5 billion in 2023**

### Precision Medicine Market Growth



Market Size in  
\$ Billions USD

**+ 185% (CAGR) of 16.3%**

<https://www.grandviewresearch.com/industry-analysis/precision-medicine-diagnostics-therapeutics-market>






# Onco-Innovations Milestones



## Achieved and Anticipated





# Capital Structure

As at January 27, 2025



ONCO-INNOVATIONS

CSE: **ONC** | FSE: **W1H**

Common Shares Issued & Outstanding	43,922,500
Warrants	7,621,500
Stock Options	630,000
RSU's	1,300,000
Issued & Outstanding Fully Diluted	52,844,000





# Highlights of Onco-Innovations

Why Onco Innovations?  
An Undervalued Unique  
Opportunity in Oncology



## ✓ Proprietary Drug Portfolio

- Revolutionary colorectal cancer therapies addressing an initial and growing \$15 billion market
- Fully owned PKNP platform and Onco10™ for targeted drug development and defined clinical pathways and partners

## ✓ World-Class Leadership Team

- Decades of experience in biotechnology, AI, and clinical innovation
- Success in public offerings, global partnerships, and award-winning research including Nobel Prizes

## ✓ Clear Path to Commercialization

- Strategic milestones set for drug launches and global market expansion
- Backed by clinical validation, partnerships, and a scalable growth model

## ✓ Massive Market Opportunities

- The global oncology market exceeds \$200 billion, with precision medicine projected to grow by 184.8% by 2030
- Oncology, diagnostics, and precision medicine combined exceed \$750B by 2030

## ✓ Strong Competitive Advantage

- First-mover advantage combining proprietary drug therapies with advanced AI technology
- Synergies between Onco and Inka create unmatched scalability and innovation

## ✓ AI Integration Through Inka Health & Big Pharma Clients

- Industry-leading AI solutions enhancing precision diagnostics and personalized treatment
- Proven to reduce diagnostic timelines by 50%, enabling faster patient outcomes







# ONCO-INNOVATIONS

CSE: ONC | FSE: W1H

Onco-Innovations Corp.



1309 – 7th Street SW  
Calgary, Alberta, Canada  
T2R 1A5

Thank You



1 (888) 261 – 8055



[www.oncoinnovations.com](http://www.oncoinnovations.com)



[investors@oncoinnovations.com](mailto:investors@oncoinnovations.com)

CSE: **ONCO** | FSE: W1H